Medicare's Ozempic coverage limited to diabetes—what patients need to know

Ozempic, a medication containing semaglutide, is approved by the FDA to help manage blood sugar in people with type 2 diabetes. Medicare Part D covers its use for this purpose but excludes treatment for prediabetes or weight loss. The rules differ from those for Wegovy, another semaglutide drug approved specifically for weight management. Ozempic's benefits extend beyond blood sugar control. It lowers the risk of heart attack and stroke in adults with type 2 diabetes and existing cardiovascular disease. The drug also helps reduce complications linked to chronic kidney disease in the same patient group.

While Medicare Part D does not cover Ozempic for prediabetes, Part B offers a separate prevention programme. The Medicare Diabetes Prevention Program (MDPP) runs for two years, focusing on diet, exercise, and weight management. Many private insurance plans, including Medicare Advantage, may still cover Ozempic for its approved diabetes uses. Prediabetes, a condition where blood sugar levels are higher than normal but not yet diabetic, can progress to type 2 diabetes over time. Medicare's Part B programme aims to stop this transition by promoting healthier habits.

Medicare's coverage of Ozempic remains limited to FDA-approved diabetes treatment. Patients with prediabetes or those seeking weight loss must rely on alternative programmes like MDPP. The distinction between Ozempic and Wegovy reflects different approvals and insurance policies for each drug.